CorMatrix Cardiovascular Inc. is set to begin early feasibility trials of a tricuspid valve that is designed to serve as a temporary replacement and support growth of a new native valve.
The company announced March 2 that FDA has approved an investigational device exemption for an early feasibility study of its...
Welcome to Medtech Insight
Create an account to read this article
Already a subscriber?